Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
STOK Stock Forecast 2026-2027
$29.11
Current Price
$1.81B
Market Cap
Buy 13
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to STOK Price Targets
+106.1%
To High Target of $60.00
+51.2%
To Median Target of $44.00
+20.2%
To Low Target of $35.00
STOK Price Momentum
-7.2%
1 Week Change
-3.8%
1 Month Change
+135.7%
1 Year Change
-8.3%
Year-to-Date Change
-27.6%
From 52W High of $40.22
+149.0%
From 52W Low of $11.69
📊 TOP ANALYST CALLS
Did STOK Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Stoke is one of their latest high-conviction picks.
Latest STOK Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, STOK has a bullish consensus with a median price target of $44.00 (ranging from $35.00 to $60.00). The overall analyst rating is Strong Buy (9.8/10). Currently trading at $29.11, the median forecast implies a 51.2% upside. This outlook is supported by 13 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
STOK Analyst Ratings
13
Buy
0
Hold
0
Sell
STOK Price Target Range
Low
$35.00
Average
$44.00
High
$60.00
Current: $29.11
Latest STOK Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for STOK.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jul 13, 2026 | Goldman Sachs | Kevin Strang | Buy | Initiates | $44.00 |
| May 11, 2026 | BTIG | Thomas Shrader | Buy | Reiterates | $39.00 |
| Mar 20, 2026 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Mar 19, 2026 | BTIG | Buy | Reiterates | $N/A | |
| Mar 18, 2026 | Wedbush | Outperform | Maintains | $N/A | |
| Mar 18, 2026 | Chardan Capital | Buy | Maintains | $N/A | |
| Mar 17, 2026 | Wedbush | Outperform | Maintains | $N/A | |
| Mar 17, 2026 | Needham | Buy | Maintains | $N/A | |
| Feb 24, 2026 | Wolfe Research | Outperform | Initiates | $N/A | |
| Jan 12, 2026 | Wedbush | Outperform | Maintains | $N/A | |
| Jan 5, 2026 | Chardan Capital | Buy | Maintains | $N/A | |
| Jan 5, 2026 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Dec 15, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Nov 5, 2025 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Nov 5, 2025 | Wedbush | Outperform | Maintains | $N/A | |
| Nov 5, 2025 | BTIG | Buy | Reiterates | $N/A | |
| Nov 3, 2025 | JP Morgan | Neutral | Maintains | $N/A | |
| Oct 13, 2025 | BTIG | Buy | Maintains | $N/A | |
| Oct 10, 2025 | Needham | Buy | Maintains | $N/A | |
| Aug 13, 2025 | Chardan Capital | Buy | Maintains | $N/A |
Stoke Therapeutics Inc. (STOK) Competitors
The following stocks are similar to Stoke based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
STOK
Stoke Therapeutics
mkt cap
1.95B
Stoke Therapeutics Inc. (STOK) Financial Data
Stoke Therapeutics Inc. has a market capitalization of $1.81B with a P/E ratio of 48.8x. The company generates $32.08M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is -96.1% quarter-over-quarter, while maintaining an operating margin of -857.6% and return on equity of -45.6%.
Valuation Metrics
Market Cap
$1.81B
Enterprise Value
$1.49B
P/E Ratio
48.8x
PEG Ratio
-0.3x
Price/Sales
56.7x
Growth & Margins
Revenue Growth (YoY)
-96.1%
Gross Margin
N/A
Operating Margin
-857.6%
Net Margin
0.0%
EPS Growth
-96.1%
Financial Health
Cash/Price Ratio
+18.9%
Current Ratio
9.0x
Debt/Equity
0.9x
ROE
-45.6%
ROA
-27.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Stoke Therapeutics Inc. (STOK) Business Model
About Stoke Therapeutics Inc.
What They Do
Develops RNA-based medicines for genetic diseases.
Business Model
The company utilizes its proprietary TANGO platform to create RNA-targeted therapies that enhance protein expression from healthy genes. It generates revenue primarily through collaborations, such as its partnership with Biogen for its lead product, zorevunersen, which is in Phase 3 trials for Dravet syndrome.
Additional Information
Founded in 2014 and based in Bedford, Massachusetts, Stoke Therapeutics is focused on addressing severe genetic conditions through innovative treatments. The company is actively exploring therapies for other diseases, including autosomal dominant optic atrophy, positioning itself as a leader in precision medicine.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
170
CEO
Mr. Ian F. Smith A.C.A., C.P.A.
Country
United States
IPO Year
2019
Website
www.stoketherapeutics.comStoke Therapeutics Inc. (STOK) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Ionis Begins Dosing in Phase I/II Dravet Syndrome Study
IONS doses first patient in the phase I/II ASCEND study of ION337, marking a key step in developing a potential disease-modifying treatment for Dravet syndrome.
Jul 14, 2026
By Zacks Equity Research
Analyst Blog
Latest News
Quick Summary
Stoke Therapeutics has completed enrollment of 162 patients in the Phase 3 EMPEROR study for zorevunersen, its investigational treatment for Dravet syndrome.
Why It Matters
Completion of patient enrollment in a Phase 3 study for a potential treatment in Dravet syndrome signals progress for Stoke Therapeutics, impacting its stock valuation and market confidence.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Stoke Therapeutics granted stock options for 103,020 shares to nine individuals, effective June 15, 2026. The company is focused on RNA medicine, with zorevunersen targeting Dravet syndrome.
Why It Matters
Stoke Therapeutics' stock options grant may indicate confidence in future growth, potentially impacting share price and investor interest as it advances its treatment for Dravet syndrome.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Stoke Therapeutics, Inc. (STOK) presented at the Goldman Sachs 47th Annual Global Healthcare Conference, providing insights into the company's developments and future plans.
Why It Matters
Stoke Therapeutics' presentation at a prominent healthcare conference may signal key developments or strategic insights, influencing market perception and stock performance in biotech.
Source: Seeking Alpha
Market Sentiment:
Neutral
4 Biotech Stocks Investors Should Watch in 2026
1 month ago
Quick Summary
New drug approvals and strong pipeline progress in the Zacks Biomedical and Genetics industry support LQDA, IMNM, STOK, and IMCR amid macroeconomic uncertainty.
Why It Matters
New drug approvals and strong pipelines indicate potential growth for LQDA, IMNM, STOK, and IMCR, suggesting resilience and investment opportunities in the biomedical sector amid economic uncertainty.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Stoke Therapeutics (STOK) shows signs of support following a recent decline, with a hammer chart pattern and analysts raising earnings estimates, suggesting potential for a turnaround.
Why It Matters
Stoke Therapeutics shows signs of recovery with a hammer chart pattern and upgraded earnings estimates from analysts, indicating potential for a price rebound and improved investor sentiment.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Stoke Therapeutics (Nasdaq: STOK) is developing zorevunersen as a potential treatment for Dravet syndrome. CEO Ian F. Smith and Chief Patient Officer Jason Hoitt will present at an upcoming investor event.
Why It Matters
Stoke Therapeutics' presentation by key executives highlights its innovative approach in RNA medicine and potential breakthroughs in treating Dravet syndrome, which could drive investor interest and stock value.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About STOK Stock
What is Stoke Therapeutics Inc.'s (STOK) stock forecast for 2027?
Based on our analysis of 4 Wall Street analysts, Stoke Therapeutics Inc. (STOK) has a median price target of $44.00. The highest price target is $60.00 and the lowest is $35.00.
Is STOK stock a good investment in 2027?
According to current analyst ratings, STOK has 13 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $29.11. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for STOK stock?
Wall Street analysts predict STOK stock could reach $44.00 in the next 12 months. This represents a 51.2% increase from the current price of $29.11. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Stoke Therapeutics Inc.'s business model?
The company utilizes its proprietary TANGO platform to create RNA-targeted therapies that enhance protein expression from healthy genes. It generates revenue primarily through collaborations, such as its partnership with Biogen for its lead product, zorevunersen, which is in Phase 3 trials for Dravet syndrome.
What is the highest forecasted price for STOK Stoke Therapeutics Inc.?
The highest price target for STOK is $60.00 from at , which represents a 106.1% increase from the current price of $29.11.
What is the lowest forecasted price for STOK Stoke Therapeutics Inc.?
The lowest price target for STOK is $35.00 from at , which represents a 20.2% increase from the current price of $29.11.
What is the overall STOK consensus from analysts for Stoke Therapeutics Inc.?
The overall analyst consensus for STOK is bullish. Out of 4 Wall Street analysts, 13 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $44.00.
How accurate are STOK stock price projections?
Stock price projections, including those for Stoke Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 17, 2026 3:18 AM UTC